Ultima-CJC1295 no DAC 2mg

MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE GHRH Peptide ,

CJC-1295 is an artificial analogue of growth hormone-releasing hormone (GHRH) that consists of 30 amino acids. It has proven to be very effective in enhancing the secretion of growth hormone and IGF-1, without adversely impacting the natural pulsatility of GH secretion.

CJC-1295 is frequently paired with Ipamorelin due to its greater specificity as a GHRH. This peptide promotes similar increases in growth hormone levels but does not stimulate appetite or raise cortisol, acetylcholine, prolactin, or aldosterone levels like other peptides in its category. It is well-tolerated and works exceptionally well in conjunction with Ipamorelin.

CJC-1295 also supports deep slow-wave sleep, which is essential for optimal muscle growth, memory retention, and overall rejuvenation.

GHRH is synthesized in the hypothalamus and its pulsatile release stimulates the pituitary gland to release GH. GHRH has a very short half-life of just a few minutes (the half-life is the duration required to eliminate half the substance from the bloodstream; shorter half-lives indicate rapid removal and reduced effects).

The first 29 amino acids of GHRH constitute its active part, available as a manufactured peptide called Sermorelin. Sermorelin has been modified to extend its half-life to 30 minutes, creating CJC-1295. Further enhancement occurred by adding a Drug Affinity Complex (DAC), which binds to the blood protein albumin, extending its half-life to eight days, thus yielding CJC-1295 + DAC. CJC-1295 can also be formulated without DAC to simulate a more typical physiological GH spike each night.

The extended half-life resulting from DAC attachment means that injections are only needed once or twice a week. However, the prolonged half-life and relatively stable blood levels provide a continuous stimulus for pituitary GH release through the GHRH receptor, which is not natural. This can reduce GH pulse amplitude and consequently lower GH stimulation in tissues.

When using a long-acting CJC molecule, it's advisable to implement 'hormone holidays' of three months every three to six months to allow the pituitary gland time to 'recover.' During these breaks, Sermorelin is recommended instead of CJC-1295 + DAC.

These 'hormone holidays' may also help reduce the potential for developing GH resistance. Such resistance, or insensitivity, could arise from antibodies forming that bind to and inactivate GH, or a reduced number of GH receptors in tissues (down-regulation). These concerns are theoretical, as no long-term studies have been conducted to explore them thoroughly.

Possible side effects of CJC-1295 may include injection site reactions (such as irritation, redness, swelling, pain, or itching), headaches, diarrhea, vasodilation (including flushing, warmth, temporary low blood pressure), nausea, and abdominal discomfort.